Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sergliflozin etabonate

Known as: 2-((4-methoxyphenyl)methyl)phenyl 6-O-ethoxycarbonylglucopyranoside, 2-(4-Methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-beta-D-glucopyranoside 
A benzylphenol glucoside and selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Its prodrug form… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Poor pharmacokinetic stability is one of the issues of O-glucoside SGLT2 inhibitors in clinical trials, hence C-glucoside… Expand
  • figure 1
2014
2014
Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine and improve blood glucose… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of sodium‐dependent glucose cotransporter 2… Expand
2010
2010
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium‐dependent glucose cotransporter… Expand
Highly Cited
2009
Highly Cited
2009
The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has… Expand
2009
2009
Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves… Expand
Highly Cited
2008
Highly Cited
2008
The kidney contains two Na+/glucose cotransporters, called SGLT2 and SGLT1, arranged in series along the length of the proximal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 1
Highly Cited
2007
Highly Cited
2007
The low-affinity sodium glucose cotransporter (SGLT2), which is expressed specifically in the kidney, plays a major role in renal… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2